Publications by authors named "Mei-Yi Sim"

Claim this Profile
U
Urine osmolality assessment through the integration of urea hydrolysis and impedance measurement.
Tian Fook Kong, Xinhui Shen, Mei Yi Sim, Jin Yong, Tze Kiat Ng

Lab Chip· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility and utility of facemask sampling in the detection of SARS-CoV-2 during an ongoing pandemic.
Dorothy Hui Lin Ng, Mei Yi Sim, Hong Hong Huang, Jean Xiang Ying Sim, Jenny Guek Hong Low

Eur J Clin Microbiol Infect Dis· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-survivin effect of the small molecule inhibitor YM155 in RCC cells is mediated by time-dependent inhibition of the NF-κB pathway.
Mei Yi Sim, John Shyi Peng Yuen, Mei Lin Go

Sci Rep· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The mechanistic effects of the dioxonaphthoimidazolium analog YM155 in renal cell carcinoma cell cycling and apoptosis.
Mei Yi Sim, Mei Lin Go, John Shyi Peng Yuen

Life Sci· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
Mei Yi Sim, Hung Huynh, Mei Lin Go, John Shyi Peng Yuen

PLoS One· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiproliferative, DNA intercalation and redox cycling activities of dioxonaphtho[2,3-d]imidazolium analogs of YM155: A structure-activity relationship study.
Si-Han Sherman Ho, Mei-Yi Sim, Wei-Loong Sherman Yee, Tianming Yang, Shyi-Peng John Yuen

Eur J Med Chem· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD1d expression in renal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival.
Tsung Wen Chong, Fera Yiqian Goh, Mei Yi Sim, Hong Hong Huang, Aye Aye Thike

J Clin Pathol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
John Shyi Peng Yuen, Mei Yi Sim, Hong Gee Sim, Tsung Wen Chong, Weber Kam On Lau

Int J Oncol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis